Nuravax and Institute for Molecular Medicine Announce Publication of Phase 1 Results for AV-1959R Amyloid-Beta Vaccine
Randomized, placebo-controlled study in 16 cognitively unimpaired participants met safety and immunogenicity objectives; all 12 vaccine recipients developed anti-Aβ antibodies after two priming doses Randomized, double-blind, placebo-controlled Phase 1 trial enrolled 16 cognitively...
Short extract only — this publisher licenses its text. Read the full release at the source.
Cancel anytime · CA$99/month


